Hu P - Search Results

1

Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.

Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P, Epstein AL. Sadun RE, et al. Among authors: hu p. Clin Cancer Res. 2007 Jul 1;13(13):4016-25. doi: 10.1158/1078-0432.CCR-07-0016. Clin Cancer Res. 2007. PMID: 17606736

2

Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.

Li J, Hu P, Khawli LA, Epstein AL. Li J, et al. Among authors: hu p. Cancer Res. 2003 Dec 1;63(23):8384-92. Cancer Res. 2003. PMID: 14679000

3

NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.

Khawli LA, Hu P, Epstein AL. Khawli LA, et al. Among authors: hu p. Clin Cancer Res. 2005 Apr 15;11(8):3084-93. doi: 10.1158/1078-0432.CCR-04-2310. Clin Cancer Res. 2005. PMID: 15837764

4

Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.

Zhang N, Khawli LA, Hu P, Epstein AL. Zhang N, et al. Among authors: hu p. Clin Cancer Res. 2005 Aug 15;11(16):5971-80. doi: 10.1158/1078-0432.CCR-05-0554. Clin Cancer Res. 2005. PMID: 16115941

5

Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.

Liu A, Hu P, Khawli LA, Epstein AL. Liu A, et al. Among authors: hu p. Clin Cancer Res. 2005 Dec 1;11(23):8492-502. doi: 10.1158/1078-0432.CCR-05-1411. Clin Cancer Res. 2005. PMID: 16322313

6

B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.

Liu A, Hu P, Khawli LA, Epstein AL. Liu A, et al. Among authors: hu p. J Immunother. 2006 Jul-Aug;29(4):425-35. doi: 10.1097/01.cji.0000208260.80791.3d. J Immunother. 2006. PMID: 16799338

7

Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.

Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, Khawli LA, Hu P, Epstein AL. Zhang N, et al. Among authors: hu p. Clin Cancer Res. 2007 May 1;13(9):2758-67. doi: 10.1158/1078-0432.CCR-06-2343. Epub 2007 Apr 25. Clin Cancer Res. 2007. PMID: 17460060

8

Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.

Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H, Lutsiak ME, Khawli LA, Epstein AL. Hu P, et al. Clin Cancer Res. 2008 Jan 15;14(2):579-88. doi: 10.1158/1078-0432.CCR-07-0940. Clin Cancer Res. 2008. PMID: 18223234

9

A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models.

Zheng L, Ren L, Kouhi A, Khawli LA, Hu P, Kaslow HR, Epstein AL. Zheng L, et al. Among authors: hu p. Clin Cancer Res. 2020 Jul 15;26(14):3694-3706. doi: 10.1158/1078-0432.CCR-19-3417. Epub 2020 Apr 9. Clin Cancer Res. 2020. PMID: 32273277

10

Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins.

Sharifi J, Khawli LA, Hu P, Li J, Epstein AL. Sharifi J, et al. Among authors: hu p. Hybrid Hybridomics. 2002 Dec;21(6):421-32. doi: 10.1089/153685902321043954. Hybrid Hybridomics. 2002. PMID: 12573106

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,987 results

Search Page

Filters